311 related articles for article (PubMed ID: 27426872)
21. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
22. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial.
Bridoux F; Fermand JP
Adv Chronic Kidney Dis; 2012 Sep; 19(5):333-41. PubMed ID: 22920644
[TBL] [Abstract][Full Text] [Related]
23. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
25. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
26. Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.
Goel SK; Granger D; Bellovich K; Marin M; Qu H; El-Ghoroury M
Transplant Proc; 2011 Sep; 43(7):2784-8. PubMed ID: 21911163
[TBL] [Abstract][Full Text] [Related]
27. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
28. Renal disease in multiple myeloma: current perspectives.
Iggo N; Parsons V
Nephron; 1990; 56(3):229-33. PubMed ID: 2077403
[No Abstract] [Full Text] [Related]
29. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Heyne N; Denecke B; Guthoff M; Oehrlein K; Kanz L; Häring HU; Weisel KC
Ann Hematol; 2012 May; 91(5):729-735. PubMed ID: 22170517
[TBL] [Abstract][Full Text] [Related]
30. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
31. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
[TBL] [Abstract][Full Text] [Related]
34. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
36. [The role of nephrologist in treatment of multiple myeloma].
Kes P; Basić-Jukić N; Jurić I; Brunetta B
Acta Med Croatica; 2008; 62 Suppl 1():37-43. PubMed ID: 18578331
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
[TBL] [Abstract][Full Text] [Related]
38. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
Sinisalo M; Silvennoinen R; Wirta O
Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
[TBL] [Abstract][Full Text] [Related]
39. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
40. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
